Markets:

Overview

News

Currencies

International

Treasuries

IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

29.60 +1.28 (+4.52%)

Streaming Delayed Price Updated: 1:58 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about IDEAYA Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

IDEAYA Biosciences: Q1 Earnings Insights ↗

May 09, 2023

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 24, 2023

Via Benzinga

Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 24, 2023

Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.

Via Benzinga

IDEAYA Biosciences Inc. (NASDAQ: IDYA) Leading the Way in Monday Trading Based on Percentage Gain

April 24, 2023

Via Investor Brand Network

IDEAYA Biosciences's Return On Capital Employed Insights ↗

March 09, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 28, 2022 ↗

December 28, 2022

Via Benzinga

Where IDEAYA Biosciences Stands With Analysts ↗

October 27, 2022

Analysts have provided the following ratings for IDEAYA Biosciences (NASDAQ:IDYA) within the last quarter:

Via Benzinga

Nasdaq Turns Lower Ahead Of Big Week For Tech ↗

April 24, 2023

The Nasdaq Composite Index has begun to slip deeper into the red ahead of this week's slew of Big Tech earnings.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

IDEAYA Biosciences Touts Encouraging Data From Combo Therapy For Rare Eye Cancer Impacting Around 14,000 In US and Europe ↗

April 24, 2023

Via Benzinga

IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial ↗

September 12, 2022

Via Benzinga

US Stocks Edge Higher; Coca-Cola Posts Upbeat Results ↗

April 24, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones gaining around 30 points on Monday. Following the market opening Monday, the Dow traded up 0.10% to 33,843.10 while the NASDAQ rose...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 24, 2023

Via Benzinga

Philips, Credit Suisse And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

April 24, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023 ↗

March 23, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

Buy/Sell: Wall Street's Top 5 Stock Calls This Week - Sunday, Jan. 1 ↗

January 01, 2023

What was Wall Street buzzing about this past week? Let's take a closer look at the top 5 buy calls made by Wall Street’s best analysts during the week of Dec. 26-30, 2022.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022 ↗

October 27, 2022

Upgrades

Via Benzinga

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 15, 2022

Via Benzinga

Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗

September 15, 2022

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome...

Via Benzinga

Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket ↗

September 15, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

September 15, 2022

Good morning! It's time for another dive into the biggest pre-market stock movers as we see why shares are moving Thursday morning!

Via InvestorPlace

Arconic, Rhythm Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

September 15, 2022

U.S. stock futures traded higher this morning ahead of several economic reports. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why Ideaya Biosciences Shares Are Falling Sharply During Wednesday's After-Hours Session ↗

September 14, 2022

Ideaya Biosciences Inc (NASDAQ: IDYA) shares are trading lower by 10.07% to $11.25 during Wednesday's after-hours session. The company announced an $80 million common stock offering.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 14, 2022

Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.

Via Benzinga

Where IDEAYA Biosciences Stands With Analysts ↗

September 13, 2022

Over the past 3 months, 4 analysts have published their opinion on IDEAYA Biosciences (NASDAQ:IDYA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session ↗

September 12, 2022

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.